View in EDS HTML Full Text PDF Full Text

Efficacy and Safety of Biosimilar QL1207 vs. the Reference Aflibercept for Patients with Neovascular Age-Related Macular Degeneration: A Randomized Phase 3 Trial.

Saved in:
Bibliographic Details
Title: Efficacy and Safety of Biosimilar QL1207 vs. the Reference Aflibercept for Patients with Neovascular Age-Related Macular Degeneration: A Randomized Phase 3 Trial.
Authors: Li, Bing1 (AUTHOR), Fan, Ke2 (AUTHOR), Zhang, Tonghe3 (AUTHOR), Wu, Zhifeng4 (AUTHOR), Zeng, Siming5 (AUTHOR), Zhao, Mingwei6 (AUTHOR), Ren, Qian7 (AUTHOR), Zheng, Dongping8 (AUTHOR), Wang, Lifei9 (AUTHOR), Liu, Xiaoling10 (AUTHOR), Han, Mei11 (AUTHOR), Song, Yanping12 (AUTHOR), Ye, Jian13 (AUTHOR), Pei, Cheng14 (AUTHOR), Yi, Jinglin15 (AUTHOR), Wang, Xian16 (AUTHOR), Peng, Hui17 (AUTHOR), Zhang, Hong18 (AUTHOR), Zhou, Zhanyu19 (AUTHOR), Liang, Xiaoling20 (AUTHOR)
Source: Ophthalmology & Therapy. Jan2024, Vol. 13 Issue 1, p353-366. 14p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:21938245
DOI:10.1007/s40123-023-00836-4